Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bethanechol in Localized Pancreatic Adenocarcinoma
NCT03572283Phase 1Completed
- Sponsor
- Columbia University
- Start
- Apr 2018
- Primary completion
- Jul 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of bethanechol in pancreatic ductal adenocarcinoma (PDAC), sponsored by Columbia University. Primary endpoint: Change in cell proliferation by Ki-67 expression in tumor cells. Started Apr 2018; status: completed.
02
Drugs
bethanechol
03
Conditions
pancreatic ductal adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT03572283.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03572283.